QQ客服 官方微博 反馈留言

	Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study
	Wu, Jianqiu; Song, Yongping; Su, Liping; Xu, Li; Chen, Tingchao; Zhao, Zhiyun; Zhang, Mingzhi; Li, Wei; Hu, Yu; Zhang, Xiaohong
刊名	BMC CANCER
	2016
卷号	16
关键词	DLBCL R-CHOP Chemotherapy HBV infection HBsAg
ISSN号	1471-2407
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3429560
专题	昆明医科大学
推荐引用方式 GB/T 7714	Wu, Jianqiu,Song, Yongping,Su, Liping,et al. Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study[J]. BMC CANCER,2016,16.
APA	Wu, Jianqiu.,Song, Yongping.,Su, Liping.,Xu, Li.,Chen, Tingchao.,...&Feng, Jifeng.(2016).Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study.BMC CANCER,16.
MLA	Wu, Jianqiu,et al."Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study".BMC CANCER 16(2016).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。